Technical Data
V2110-04A
Vascular Endothelial Growth Factor, Recombinant, Human (VEGF)
2ug
10ug
10ug
|
Technical Data |
|
V2110-04A |
Vascular Endothelial Growth Factor, Recombinant, Human (VEGF) |
2ug 10ug |
| Growth Factors, Cytokines | Storage: -20°CShipping: RT |
|
Vascular endothelial growth factor-A was originally isolated from tumor cells and referred to as Tumor Angiogenesis Factor or Vascular Permeability Factor. Although expressed at high levels in certain tumor-derived cells it is produced by a wide variety of cell types. In addition to stimulating vascular growth and vascular permeability it may play a role in stimulating Vasolidation via nitric oxide-dependent pathways. Alternative splicing of the mRNA for VEGF-A results in several isoforms of the protein being produced. Rat and bovine VEGF are one amino acid shorter than the human factor, and the bovine and human sequences show a homology of 95 percent. In contrast to other factors mitogenic for endothelial cells such as FGF-1, FGF-2 and PDGF, VEGF is synthesized as a precursor containing a typical hydrophobic secretory signal sequence of 26 amino acids. Glycosylation is not required for efficient secretion of VEGF. Recombinant Human VEGF is a double, non-glycosylated, polypeptide chain containing 165 amino acids and having a molecular mass of 38231 Dalton. Sequence: The sequence of the first five N-terminal amino acids was determined and was found to be Ala-Pro-Met-Ala-Glu. Biological Activity: The biological activity is determined by the dose-dependent stimulation of the proliferation of human umbilical vein endothelial cells (HUVEC) using a concentration range of 1.0-8.0ng/ml. Protein Content: Protein quantitation was carried out by two independent methods: 1. UV spectroscopy at 280nm using the absorbency value of 0.2875 as the extinction coefficient for a 0.1% (1mg/ml) solution. This value is calculated by the PC GENE computer analysis program of protein sequences (IntelliGenetics). 2. Analysis by RP-HPLC, using a calibrated solution of VEGF as a Reference Standard. Storage and Stability: Store at -20°C. Reconstitute to nominal volume by adding sterile dH2O, 0.1% HSA or BSA and store at -20°C. Reconstituted product is stable for 12 months at -20°C. For maximum recovery of product, centrifuge the original vial prior to removing the cap. Further dilutions can be made in assay buffer. |
Source: Recombinant, Human (Escherichia coli) Purity: >98% by RP-HPLC and reducing/non-reducing SDS-PAGE (silver stained) Concentration: ~0.1mg/ml Form: Supplied as a lyophilized powder. No additives. Reconstitute with sterile ddH2O, 0.1% HSA or BSA to a concentration 0.1mg/ml Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological. |
|
1. Overproduction of VEGF concomitantly expressed with its receptors promotes growth and survival of melanoma cells through MAPK and PI3K signaling. Graells J, Vinyals A, Llorens A, Fabra A, J Invest Dermatol 2004 Dec;123(6):1151-61 2. Differential effects of antiangiogenic compounds in neovascularization, leukocyte recruitment, VEGF production, and tumor growth in mice. Belo AV, Barcelos LS, Ferreira MA, Cancer Invest 2004;22(5):723-9 3. Molecular regulation of the VEGF family -- inducers of angiogenesis and lymphangiogenesis. McColl BK, Stacker SA, APMIS 2004 Jul-Aug;112(7-8):463-80 4. Characterization of vascular endothelial growth factor (VEGF) in the uterine cervix over pregnancy: effects of denervation and implications for cervical ripening. Mowa CN, Jesmin S, Usip S, Papka R, J Histochem Cytochem 2004 Dec;52(12):1665-74 5. VEGF concentrations in pregnancy. Bussen S, Dietl J, Am J Obstet Gynecol 2004 Nov;191(5):1834 6. The involvement of growth hormone (GH), insulin-like growth factors (IGFs) and vascular endothelial growth factor (VEGF) in diabetic kidney disease. Flyvbjerg A, Khatir DS, Dagnaes-Hansen F, Curr Pharm Des 2004;10(27):3385-94.
|
||